Description
Key facts
Cell type:HEK-293,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Next Generation Sequencing,Western blot,
Mutation description:Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift = 99%
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-SDHA, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Succinate dehydrogenase complex flavoprotein subunit A (SDHA) also known as complex II Fp or SDH2 plays an important role in the mitochondrial electron transport chain and the tricarboxylic acid (TCA) cycle. It functions as a flavoprotein oxidoreductase catalyzing the oxidation of succinate to fumarate. With a molecular mass of approximately 72 kDa SDHA is expressed in the inner mitochondrial membrane of eukaryotic cells where it is a core component of the succinate dehydrogenase complex (SDHC). The complex is essential for cellular respiration and energy production.
Biological function summary
SDHA participates in the TCA cycle by accepting electrons from succinate which it donates to the coenzyme Q in the electron transport chain. This essential role connects SDHA to the regulation of ATP production in cells. SDHA operates as part of the larger succinate dehydrogenase (SDH) complex which includes other subunits such as SDHB SDHC and SDHD. This structurally integrated multisubunit complex influences mitochondrial integrity and cellular energy homeostasis.
Pathways
SDHA is deeply involved in the TCA cycle and oxidative phosphorylation pathway. As a part of these pathways it links to other critical enzymes such as fumarase and aconitase working in concert to drive the conversion of biochemical fuel into usable cellular energy. Its interactions with coenzyme Q and cytochrome complex enzymes are important for electron flow and proton gradient formation across the mitochondrial membrane. Such interactions are central to cellular respiration and energy generation.
Mutations in SDHA correlate with various mitochondrial diseases and cancer syndromes. Specifically SDHA mutations have an association with Leigh syndrome and certain types of mitochondrial complex II deficiency. These mutations disrupt the function of the SDH complex causing metabolic imbalances and energy production issues. Furthermore the integral interaction of SDHA with other SDH subunits means that alterations can impact this entire enzymatic complex with implications for cellular respiration and disease progression.
